| Literature DB >> 21745712 |
Yoko Matsuda1, Toshiyuki Ishiwata, Kazuya Yamahatsu, Kiyoko Kawahara, Masahito Hagio, Wei-Xia Peng, Tetsushi Yamamoto, Nando Nakazawa, Tomoko Seya, Yoshiharu Ohaki, Zenya Naito.
Abstract
Fibroblast growth factor receptor 2 (FGFR2) is considered a novel therapeutic target for various cancer. We used a silencing strategy to clarify the effect of reduced FGFR2 expression in human colorectal cancer (CRC) cells. The invasive front of cancer cells exhibited stronger FGFR2 expression than the surface area of the cancers. FGFR2 shRNA-transfected LoVo cells inhibited cell migration, invasion and tumor growth in vitro and in vivo. Thus, FGFR2 plays important roles in CRC progression in association with tumor cell migration, invasion and growth, and FGFR2 might be a novel therapeutic target for CRC.Entities:
Mesh：
Substances：
Year: 2011 PMID： 21745712 DOI： 10.1016/j.canlet.2011.06.009
Source DB: PubMed Journal: Cancer Lett ISSN： 0304-3835 Impact factor: 8.679